CBS 2019
CBSMD教育中心
English

左主干支架

科研文章

荐读文献

Meta-Analysis of Comparison of 5-Year Outcomes of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Unprotected Left Main Coronary Artery in the Era of Drug-eluting Stents Management of left main disease: an update Provisional versus elective two-stent strategy for unprotected true left main bifurcation lesions: Insights from a FAILS-2 sub-study Successful bailout stenting strategy against lethal coronary dissection involving left main bifurcation Impact of Staging Percutaneous Coronary Intervention in Left Main Artery Disease: Insights From the EXCEL Trial Quality of Life after Everolimus-Eluting Stents or Bypass Surgery for Treatment of Left Main Disease Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main and Multivessel Coronary Artery Disease: Do We Have the Evidence? Two-year outcomes following unprotected left main stenting with first vs new-generation drug-eluting stents: the FINE registry. EuroIntervention. Long-term outcomes following mini-crush versus culotte stenting for the treatment of unprotected left main disease: insights from the Milan and New-Tokyo (MITO) registry Complex PCI procedures: challenges for the interventional cardiologist
|<<... 2 3 4 5 6 7 8 ...>>|

Editorial2018 Jul;28(5):365-366.

JOURNAL：Trends Cardiovasc Med. Article Link

Novel developments in revascularization for left main coronary artery disease

Carreras ET, Bhatt DL. Keywords: DK CRUSH; LM bifurcation lesions; evidence-based

Article Link

Please click on the "Article Link" on the right to get access to this article.


Quotation

"When PCI is used to treat LM bifurcation lesions,

DK-CRUSH is the most reasonable evidence-based approach."


>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top